Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Specialty Drug Distribution topic
No spam. Unsubscribe anytime.
Committee approves bill to broaden access to limited-distribution specialty drugs after industry objections
Summary
House Bill 1531 would require drug manufacturers to allow in-state specialty pharmacies to apply for access to limited-distribution drugs; pharmaceutical trade groups warned the measure could conflict with FDA REMS programs and create ambiguity for manufacturers.
House Bill 1531, which seeks to expand in-state access to limited-distribution specialty drugs, passed the committee after sponsors and opponents debated safety requirements, manufacturer discretion and an amendment to clarify application and review processes.
Representative Brandon Acre, sponsor, told the committee the bill is intended to enable Arkansas specialty pharmacies and hospital pharmacies (for example, UAMS, Highlands Oncology and others) to obtain access to drugs that manufacturers currently distribute only through limited, often out-of-state, networks. Acre said the change is about access and continuity, citing disruptions such as mail delays during severe weather that can prevent patients from receiving time-sensitive medications.
Pharmaceutical industry witnesses, including Kip Snyder of PhRMA and Russell Polk of BIO, opposed the measure as drafted. They said many limited-distribution networks exist for patient-safety reasons: some products require specialized storage, handling, or enrollment in FDA Risk Evaluation and Mitigation Strategies (REMS). Industry witnesses said the bill did not define “limited distribution” and could create conflicting obligations for manufacturers, raise questions about minimum volumes and impose burdensome requirements that would be difficult to implement quickly.
Sponsor Acre said the bill does not force manufacturers to recruit pharmacies; rather it creates a process for an Arkansas provider that meets product-specific qualifications to apply for access. The sponsor noted the bill includes a waiver process through the State Board of Pharmacy if manufacturers request additional requirements beyond the board’s standard criteria.
Committee members heard the industry request to slow the bill to allow more study but the committee adopted an amendment (extending implementation timelines and clarifying required standards) and passed the bill as amended. The transcript does not record a roll-call vote; committee action was by voice and the bill advanced.
